Treatment of Postmenopausal Hot Flushes (Vasomotor Symptoms)

1. Hormone Therapy (HT) — First-Line

Who gets what:

Estrogen options:

• Transdermal (preferred — lower VTE/stroke risk than oral): estradiol patch 25–100 mcg twice weekly; estradiol gel 0.6 mg/g, 1–2 pumps daily
• Oral: estradiol 1–2 mg/day; conjugated estrogens 0.3–1.25 mg/day

Progestogen options (required if uterus intact):

• Micronised progesterone 100–200 mg/day (most favourable safety profile)
• Combined patches (estradiol + norethisterone)
• Levonorgestrel IUS (alternative for endometrial protection)

Starting dose:

Key risks (from Maudsley Guidelines):

A 2025 Bayesian network meta-analysis (41 RCTs, n=14,743) found synthetic conjugated estrogens 1.25 mg most effective for VMS frequency, and drospirenone 0.5 mg + estradiol 0.5 mg most effective for severity. Transdermal estradiol gel ranked highly for frequency reduction. [PMID: 40592206]

2. Non-Hormonal Pharmacological Options

Antidepressants (SNRIs/SSRIs)

NK3 Receptor Antagonists (newest class)

A 2025 meta-analysis (10 RCTs, n=4,663) confirmed both agents achieve ≥50% reductions in VMS frequency. Elinzanetant showed a more favourable side-effect profile than fezolinetant, and additionally improved menopause-specific quality of life. [PMID: 39987726]

GABA Analogues

• Gabapentin: 300 mg nightly, up to 900 mg in divided doses — useful especially for night sweats
• Pregabalin: 75–150 mg twice daily — inconsistent evidence

Other agents

• Oxybutynin: 2.5–5 mg twice daily (anticholinergic; modest benefit)
• Clonidine: 0.1–1 mg/day oral or 0.1–0.3 mg/week transdermal — limited/inconsistent evidence; side effects (dizziness, dry mouth, constipation) limit use

3. Genitourinary Syndrome of Menopause (GSM)

4. Non-Pharmacological / Lifestyle

• Cognitive behavioural therapy (CBT): Good evidence for reducing perceived severity and bother; recommended by BMS 2025 guidelines
• Trigger avoidance: Hot drinks, spicy food, alcohol, warm environments
• Layered clothing, cool sleeping environment
• Mindfulness-based therapies: Some benefit for distress associated with VMS
• Soy isoflavones: A 2025 meta-analysis shows modest reduction in hot flush frequency, though effects are variable and evidence quality is moderate [PMID: 40718787]
• Weight loss in overweight women reduces frequency

5. Decision Framework

Hot flush severity?
│
├── Mild → Lifestyle + CBT ± soy isoflavones
│
├── Moderate–severe + no HRT contraindications
│   └── Transdermal estrogen + progestogen (if uterus intact)
│       → Gold standard; start low, titrate
│
├── Moderate–severe + HRT contraindicated / declined
│   ├── Fezolinetant 45 mg/day (NK3 antagonist — FDA approved)
│   ├── Paroxetine mesylate 7.5 mg (FDA approved, non-hormonal)
│   ├── Venlafaxine 37.5–75 mg (especially breast cancer survivors)
│   └── Gabapentin 300–900 mg (especially night sweats)
│
└── GSM prominent → Add local vaginal estrogen or ospemifene

• Harrison's Principles of Internal Medicine, 22nd ed. (2025), p. 407
• Maudsley Prescribing Guidelines in Psychiatry, 15th ed., pp. 885–887
• Pharmacological treatments network meta-analysis (2025) — PMID: 40592206
• NK3 antagonist meta-analysis (2025) — PMID: 39987726
• BMS Non-hormonal Consensus Statement 2025

Pelvic Organ Prolapse (POP) — Current & Newer Treatments

Overview of Compartments

• Anterior: Cystocele (bladder descent)
• Apical: Uterine or vaginal vault prolapse
• Posterior: Rectocele / enterocele

1. Conservative (Non-Surgical) Management

Pelvic Floor Muscle Training (PFMT)

• First-line for mild-to-moderate POP; improves symptoms and may slow progression
• Supervised physiotherapy (individualized PFMT) shown to reduce prolapse stage in RCTs (e.g., POPPY trial)

Pessaries

• Safe, reversible mechanical support — ring, Gellhorn, donut, cube types
• Effective for all compartments; improve bulge symptoms and quality of life at 12 months
• Main issues: vaginal discharge, erosion/ulceration requiring follow-up
• Particularly useful in surgical candidates who defer or are medically unfit
• Space-occupying pessaries (Gellhorn, cube) preferred for higher-grade prolapse

Local Oestrogen

• Topical vaginal oestrogen improves tissue quality, reduces erosion risk with pessary use, and addresses genitourinary syndrome of menopause (GSM) coexisting with POP

2. Surgical Management — Established Options

Transvaginal (Native Tissue) Repairs

• Recurrence rates after native tissue repair ~15–16% at 12 months; 62–70% anatomic failure at 5 years with SSLS/USLS, though symptom scores remain improved despite anatomic findings
• Colpocleisis offers low recurrence, shorter operative time, and high satisfaction in appropriate patients

Abdominal Sacrocolpopexy (ASC)

• Durability benchmark; lowest recurrence rate for apical prolapse
• Polypropylene mesh attached from vaginal apex to sacral promontory
• Longer operative time and recovery vs. vaginal approach, but superior anatomic outcomes

3. Newer & Minimally Invasive Surgical Approaches

Laparoscopic & Robotic Sacrocolpopexy

• Minimally invasive equivalents of abdominal sacrocolpopexy
• Robotic-assisted sacrocolpopexy offers superior 3D visualization, reduced blood loss, precise suture placement, and faster recovery
• Outcomes comparable to open ASC; growing adoption supported by AI-guided robotic integration
• Uterine-preserving variant (sacrohysteropexy) increasingly preferred to avoid hysterectomy-related pelvic floor weakening

Uterine Preservation Techniques

• Sacrohysteropexy (laparoscopic/robotic) and transvaginal hysteropexy are gaining traction
• Avoids the increased POP risk associated with hysterectomy itself
• A 2025 meta-analysis confirmed hysterectomy increases subsequent pelvic floor disorder risk [PMID: 40120730]

Next-Generation Transvaginal Mesh Systems

• Classic first-generation polypropylene mesh was widely restricted/withdrawn due to high complication rates (mesh exposure 11.8%; reoperation for mesh 6.1% — Cochrane 2024, PMID: 38477494)
• New-generation lightweight, macroporous mesh (e.g., partially absorbable PGACL/polypropylene minimesh for SSL fixation): combines absorbable component (absorbed in 90–120 days) leaving lighter residual mesh; early data show 96% anatomic success with lower complication rates
• Skeletonized "pelvic harness" mesh: ~75% of material removed, mimicking ligamentary vaginal attachments — comparable anatomic outcomes to full mesh with reduced mesh burden
• Still under long-term study; regulatory status varies by country

4. Emerging / Investigational Therapies

Biodegradable Scaffolds & Smart Biomaterials

• Poly-4-hydroxybutyrate (P4HB) knitted monofilament scaffolds — ovine models show promise
• Electrospun nanofiber scaffolds (PLACL/gelatin, PLA/PU): high porosity, tunable degradation, support tissue ingrowth
• Drug-eluting mesh: estrogen- or growth factor-eluting to promote angiogenesis and integration
• Auxetic mesh geometry: overcomes pore collapse, a key failure mode of standard polypropylene mesh
• All remain investigational — require RCTs and regulatory approval before clinical use

Regenerative Medicine / Cell Therapy

• Mesenchymal stem cell (MSC)-seeded scaffolds: restore biomechanical function through controlled tissue regeneration rather than passive reinforcement
• Small extracellular vesicles (sEVs): acellular, "off-the-shelf" potential; could be used postpartum to prevent POP development
• Exosome-enriched hydrogels and gene-modified fibroblasts: in early experimental stages

3D-Printed / Patient-Specific Mesh

• Preoperative imaging (MRI/ultrasound) integrated into CAD design for personalised mesh geometry
• Melt electrowritten devices: precise architecture at fibre level; potential for patient-specific surgical constructs
• Significant manufacturing and regulatory challenges remain

Energy-Based Devices (EBDs)

• Radiofrequency and laser vaginal therapy trialled for vaginal laxity and stress urinary incontinence
• Not yet validated for anatomical POP correction — considered investigational until anatomic outcome RCT data are available

5. Current Evidence Summary (Key 2024–2025 Cochrane/Meta-Analysis)

Decision Framework

POP diagnosed (symptomatic, ≥ stage II)?
│
├── Mild / patient declines surgery / surgical risk
│   └── Pessary + PFMT + local oestrogen
│
├── Moderate–severe, sexually active, fit for surgery
│   ├── Apical defect present?
│   │   ├── Uterus in situ → Laparoscopic/robotic sacrohysteropexy (uterine-sparing)
│   │   │   OR sacrocolpopexy (laparoscopic/robotic)
│   │   └── Post-hysterectomy → Sacrocolpopexy (abdominal/laparoscopic/robotic)
│   │       or SSLS/USLS (transvaginal)
│   └── Anterior/posterior only → Colporrhaphy ± new-gen mesh augmentation
│
└── Elderly, sexually inactive, high comorbidity
    └── Colpocleisis (obliterative) — low risk, highly effective

• Berek & Novak's Gynecology, Ch. 30
• Sabiston Textbook of Surgery, 21st ed., Ch. 120
• Cochrane transvaginal mesh vs. native tissue review (2024) — PMID: 38477494
• Narrative review: mesh to modern therapies (2025) — PMC12653964
• New proposed POP treatments chapter (2025) — PMC12872679